Impact of tumor sequencing on the use of anticancer drugs

Current Opinion in Oncology

Volumn 26, Issue 3, 2014, Pages 347-356

  Thomas, François ^a,c   Desmedt, Christine ^b   Aftimos, Philippe ^c   Awada, Ahmad ^c  

^a Thomas Conseil SPRL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

anticancer drug development; cancer genome sequencing; next generation sequencing; precision medicine; predictive molecular tests

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PATIENT; CANCER THERAPY; CIRCULATING TUMOR CELL; CLINICAL RESEARCH; DNA SEQUENCE; DRUG USE; EXPERIENCE; FAMILIAL CANCER; GENE MUTATION; GENOME; GENOTYPE; HUMAN; LUNG CANCER; MEDICAL EDUCATION; MEDICAL PRACTICE; NEOPLASM; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PRESCRIPTION; PRIMARY TUMOR; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RNA SEQUENCE;

ANTINEOPLASTIC AGENTS; GENETIC TESTING; GENOME, HUMAN; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84899477743     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000078     Document Type: Review

References (61)

1. MacConaill L. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31:1815-1824.
2. Rizzo J, Buck M. Key principles and clinical applications of 'next generation' DNA sequencing. Cancer Prev Res 2012; 5:887-900.
3. Natrajan R, Reis-Filho J. Next generation sequencing applied to molecular diagnostics. Expert Rev Mol Diagn 2011; 114:425-444.
4. Ley T, Mardis E, Ding L, et al. DNA sequencing of cytogenetically normal acute myeloid leukemia genome. Nature 2008; 456:66-72.
5. Garraway L, Lander E. Lessons from cancer genomes. Cell 2013; 153:17-37.
6. Vogelstein B, Papadopoulos N, Velculescu V, et al. Cancer genome landcapes. Science 2013; 339:1546-1558.
7. Li T, Kung HJ, Mack P, Gandara D. Genotyping and genomic profiling of nonsmall-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31:1039-1049.
8. Loman N, Mistra R, Dallman T, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotech 2012; 30:434-439.
9. Quail M, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of Ion Forrest, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomic 2012; 13:341.
10. McDonald S, Mardis E, Ota D, et al. Emerging regulatory, strategic, and quality assurance challenges for biorepositories. Am J Clin Path 2012; 138:31-41.
11. Fischer R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108:479-485.
12. Van Hallen E, Wagle N, Levy M. Clinical analysis and interpretation of cancer genome data. J Clin Oncol 2013; 31:1825-1833.
13. Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucl Acids Res 2013; 41:D955-D961.
14. Gibbs J. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology. Exp Rev Mol Diagn 2001; 11:367-381.
15. Gargis A, Kalman L, Berry M, et al. Assuring the quality of next generation sequencing in clinical laboratory practice. Nat Biotech 2012; 30:1033-1036.
16. Schrijver I, Aziz N, Farkas D, et al. Opportunities and challenges associated with clinical diagnostic genome sequencing. J Mol Diagn 2012; 14:525-540.
17. Roychowdhury S, Iyer M, Robinson D, et al. Personalized oncology through integrative high throughput sequencing. A pilot study. Sci Transl Med 2011; 3:111-121.
18. Tran B, Brown A, Bedard P, et al. Feasability of real time next generation sequencing of cancer genes linked to drug response. Results from a clinical trial. Int J Cancer 2012; 132:1547-1555.
19. Ecker J. Serving up a genome feast. Nature 2012; 489:52-53.
20. Fratkin E, Bercovici S, Stephan D. The implication of Encode for diagnostics. Nat Biotech 2012; 30:1064-1065.
21. Lolkema M, Gadellaa-Van Hooijdonk C, Bredenoord A. Ethical, legal and counseling challenges surrounding the return of genetic analysis in oncology. J Clin Oncol 2012; 31:1842-1848.
22. Garraway L, Baselga J. Whole genome sequencing and cancer therapy. Is too much ever enough. Cancer Discov 2012; 2:766-768.
23. Lander E. Initial impact of the sequencing of the human genome. Nature 2011; 470:187-197.
24. Garraway L. Genomics-driven oncology. Framework for an emerging paradigm. J Clin Oncol 2013; 31:1806-1814.
25. Ciriello G, Miller M, Aksoy B, et al. Emerging landscape of oncogenic signature across human cancers. Nat Genet 2013; 45:1127-1133.
26. Lipson D, Capelletti M, Yelinsky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18:302-384.
27. Kothari V, Wei I, Shankar S, et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov 2013; 3:280-293.
28. Pantel K, Alix-Panabieres C. Real time liquid biopsy in cancer patients: facts or fictions. Clin Cancer Res 2013; 73:6384-6388.
29. Navin N, Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011; 3:31.
30. Lasken R. Single-cell sequencing in its prime. Nat Biotech 2013; 31:211-212.
31. Sleyfer S, Bogaerts J, Siu L. Designing transformative clinical trials in the cancer genome area. J Clin Oncol 2013; 31:1834-1841.
32. Planchard D, Mazieres J, Riely G, et al. Interim results of phase II study of dabrafenib in BRAF V600E mutation-positive non small cell lung cancer. J Clin Oncol 2013; 31 (Suppl); Abstract 8009.
33. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-103.
34. Ohashi K, Maruvka Y, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013; 8:1070-1080.
35. Tran B, Dancey J, Kamel-Reid S, et al. Cancer genomics: technology, discovery and translation. J Clin Oncol 2012; 30:647-660.
36. André F, Bachelot T, Campone M, et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer patients: a prospective multicentric trial (SAFIR01). J Clin Oncol 2013; 31 (Suppl); Abstract 511.
37. Welsh JS, Westervelt P, Ding L, et al. Use of whole genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011; 305:1577-1584.
38. Iyer G, Hanrahan A, Milowsky M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 388:221.
39. Kaiser J. Rare cancer successes spawn exceptional research efforts. Science 2013; 340:263.
40. Tsimberidou AM, Iskander N, Hong D, et al. Personalized medicine in a phase I clinical trial program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383.
41. Kim E, Herbst R, Wistubd I, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1:44-53.
42. Wagle N, Berger M, Davis M, et al. High throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2:82-93.
43. Vignot S, Frampton G, Soria JC, et al. Next generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with nonsmall-cell lung cancer. J Clin Oncol 2013; 31:2167-2172.
44. Conti R, Bernstein A, Villaflor M, et al. Prevalence of off-label use and spending in 2010 among patent protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013; 9:1134-1139.
45. Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating off-label drug use. N Engl J Med 2012; 367:1279-1281.
46. Overman M, Modak J, Kopez S, et al. Use of research biopsies in clinical trials: are risks and benefits adequately disclosed J Clin Oncol 2013; 31:17-22.
47. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013; 368:842-851.
48. Dawson SJ, Tsui D, Murtoza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209.
49. Forshew T, Murtoza M, Parkinson C, et al. Non invasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4:136ra68.
50. Murtoza M, Dawson S-J, Tsui D, et al. Non invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112.
51. Vignot S, Besse B, André F, et al. Discrepancies between primary tumor and metastasis. A literature review on clinically established biomarkers. Crit Rev Hematol Oncol 2012; 84:301-313.
52. Mirale S, Yaeger R, Hobor S. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.
53. Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov 2012; 2:495-502.
54. Garnett M, Edelman E, Heidorn S, et al. Systemic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 438:570-575.
55. Meril-Bernstein F, Farhangfar C, Mendelsohn J, et al. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013; 31:1849-1857.
56. Nowak F, Soria J-C, Calvo F. Tumor molecular profiling for deciding therapy. The French initiative. Nat Rev Clin Oncol 2012; 9:479-486.
57. Rodon J, Saura C, Dienstmann R, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012; 9:359-366.
58. Berry D, Herbst R, Rubin E. Design strategies for personalized therapy trials. Clin Cancer Res 2012; 18:638-644.
59. Gianni L, Pienkowski T, Im Y-U, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory, or early HER-2 positive breast cancer (Neosphere): a randomized muticentre, open-label phase 2 trial. Lancet Oncol 2012; 13:25-32.
60. Prowell T, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366:2438-2441.
61. Aman A, The clinical lung Cancer Genome Project and Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5:209ra153.